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ABSTRACT 
Background: Mechanisms underlying the association between grip strength (GS) and 
cardiovascular mortality are poorly understood. We aimed to assess the association of GS 
with a panel of cardiovascular risk markers. 
Design: Cross-sectional analysis of 3468 adults aged 50 to 75 years (1891 women) from a 
population-based sample in Lausanne, Switzerland. 
Methods: GS was measured using a hydraulic hand dynamometer. Cardiovascular risk 
markers included anthropometry, blood pressure (BP), lipids, glucose, adiposity, 
inflammatory and other metabolic markers.  
Results: In both genders, GS was negatively associated with fat mass (Pearson correlation 
coefficient: women: -0.170, men: -0.198), systolic blood pressure (women: -0.096, men: -
0.074), fasting glucose (women: -0.048, men: -0.071), log-transformed leptin (women: -
0.074, men: -0.065), log-transformed hs-CRP (women: -0.101, men: -0.079) and log-
transformed homocysteine (women: -0.109, men: -0.060). In men, GS was also positively 
associated with diastolic BP (0.068), total (0.106) and LDL-cholesterol (0.082), and negatively 
associated with interleukin-6 (-0.071); in women, GS was negatively associated with 
triglycerides (-0.064) and uric acid (-0.059). After multivariate adjustment, GS was negatively 
associated with waist circumference (change per 5 kg increase in GS: -0.82 cm in women 
and -0.77 cm in men), fat mass (-0.56% in women; -0.27% in men) and hs-CRP (-6.8% in 
women; -3.2% in men) in both genders, and with body mass index (0.22 kg/m2) and leptin (-
2.7%) in men.  
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Conclusion: GS shows only moderate associations with cardiovascular risk markers. The 
effect of muscle strength as measured by GS on CVD does not seem to be mediated by 
cardiovascular risk markers. 
Keywords: grip strength; anthropometry; blood pressure; lipids; glucose; inflammation; 
Switzerland; population-based study.  
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INTRODUCTION 
Muscle strength is an important predictor of health 1, partly explained by the 
beneficial effect of muscle resistance activities on physical fitness 2. Compared to other 
muscular tests such as trunk and knee extension or flexion, grip strength is the most 
appropriate marker of muscle strength 3 and has also been related to fitness 4. Therefore, it 
remains the simplest and most largely recommended technique to assess muscle strength in 
clinical practice 5. Grip strength has been shown to be inversely associated with overall and 
cardiovascular mortality in all age groups 6, 7, but the mechanisms involved have been less 
well established. Several cross-sectional studies assessed the associations between grip 
strength and cardiovascular (CV) risk factors, metabolic syndrome or inflammatory markers, 
but have been limited by the fact that they assessed a small set of variables 8, 9, relied on a 
small sample size 10 or were based only on elderly participants 9, 10. Further, several studies 
have suggested that fitness can exert its effects independently of physical activity levels 11, 
and that not all types of physical activity are beneficial for health 12. For instance, leisure-
time physical activity (LTPA) has been shown to be beneficial while occupational physical 
activity (OPA) has been shown to be deleterious regarding all-cause mortality 13. Still, no 
previous study took into account this finding. 
Thus, the aim of this study was to assess the associations between grip strength and 
nineteen CV risk markers using a large population-based sample aged 50-75 years from the 
city of Lausanne, Switzerland (CoLaus study), taking into account the effects of LTPA and 
OPA. 
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MATERIALS AND METHODS 
Recruitment 
A detailed description of the recruitment of the CoLaus study has been published 
previously 14. Briefly, the CoLaus study assesses the prevalence and determinants of CV 
disease in the city of Lausanne, Switzerland. A non-stratified, representative sample of the 
Lausanne population aged 35-75 years was drawn from the population register of the city.  
A letter was sent to these individuals, and subjects who volunteered to participate were 
then contacted by phone to set up an appointment. The baseline Colaus study was 
conducted between 2003 and 2006 and included 6733 participants. 
Grip strength 
Participants of the CoLaus study aged over 50 were invited to participate in a sub-
study on frailty, which included grip strength. Grip strength was assessed using the 
Baseline® Hydraulic Hand Dynamometer and positioning of the participants was done 
according to the American Society of Hand Therapists’s guidelines 5: subject seated, 
shoulders adducted and neutrally rotated, elbow flexed at 90°, forearm in neutral and wrist 
between 0 and 30° of dorsiflexion. Three measurements were performed consecutively at 
the right hand and the highest value (expressed in kg) was included in the analyses. 
Participants were also asked about their handedness. 
Exclusion criteria 
Participants were excluded if they presented any condition precluding adequate 
measurement of grip strength, i.e. pain, injury, recent surgery, osteoarthritis and 
rheumatoid arthritis, among others. 
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Other data 
A self administered questionnaire collected demographic data. Information on 
education level, job and on several lifestyle factors, including tobacco and LTPA (weekly 
number of ≥20min bouts of exercise) were also collected. OPA was categorized as non-
physical (when sitting or standing) and physical (carrying light or heavy load). History of CVD 
and CV risk factor was elicited with a standardized interview-based questionnaire filled in by 
a trained recruiter. Participants indicated if they have been diagnosed with hypertension, 
dyslipidemia, diabetes, and if they were treated for these conditions. 
Body weight and height were measured to the nearest 0.1 kg and 5 mm (Seca® scale, 
Seca® height gauge, Hamburg, Germany), with participants in light indoor clothes standing 
without shoes. Body mass index (BMI) was computed as weigth/height2. Waist 
circumference (WC) was measured at mid-way between the lowest rib and the iliac crest as 
recommended 15. Body composition was assessed by bioimpedance (Bodystat® 1500 
analyzer, Isle of Man, UK) and expressed as percentage of fat. Blood pressure (BP) was 
measured using an Omron® HEM-907 automated oscillometric sphygmomanometer after at 
least 10 minutes’ rest in a seated position and the average of the last two measurements 
was used. Hypertension was defined as a systolic BP ≥140 mmHg and/or a diastolic BP ≥90 
mmHg and/or presence of an anti-hypertensive treatment. 
A fasting venous blood sample was drawn and most measurements performed by 
the clinical laboratory of the Lausanne university hospital. Lipid markers included total and 
HDL-cholesterol, triglycerides and apolipoprotein B; LDL-cholesterol was calculated using 
the Friedewald formula if triglycerides were <4.6 mmol/L. Dyslipidemia was defined either 
by the presence of a lipid lowering drug or using the LDL-cholesterol thresholds according to 
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the PROCAM cardiovascular score adapted for Switzerland 16. Glucometabolic markers 
included glucose and insulin; diabetes was defined by a fasting glucose ≥7.0 and/or 
presence of antidiabetic drug treatment. Inflammatory markers included high sensitivity C-
reactive protein (hs-CRP), interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-α). 
Other markers included leptin, adiponectin, homocysteine and uric acid. 
CV absolute risk was calculated using the European Society of Cardiology SCORE 
recalibrated and validated for the Swiss population 17. This risk equation uses age, gender, 
smoking, systolic BP and total cholesterol to compute the 10-year absolute risk of fatal CV 
disease. No CV absolute risk was calculated for participants with history of CV disease.  
Statistical analysis 
Statistical analyses were stratified by gender and conducted using Stata version 14.0 
for windows (Stata Corp, College Station, Texas, USA). Descriptive results were expressed as 
number of participants (percentage) or as average ± standard deviation. Between-group 
comparisons were performed using chi-square or Student t-test for categorical and 
continuous variables, respectively. Natural log transformation was applied to variables with 
a skewed distribution: triglycerides, insulin, leptin, adiponectin, hs-CRP, IL-6, TNF-α and 
homocysteine. Bivariate associations were assessed by Pearson correlation. Multivariate 
associations were assessed using linear regression and the results were expressed as 
multivariate-adjusted standardized coefficients, which can be interpreted as multivariate-
adjusted correlation coefficients.   
The effect of a 5 kg increase in grip strength on the different CV risk markers was 
assessed by linear regression, and the results were expressed as coefficient and (95% 
confidence interval). For log-transformed dependent variables, results were expressed as 
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percentage change of the untransformed dependent variable and (95% confidence interval), 
as recommended 18. Multivariate analyses were conducted using linear or quadratic 
regression models and the adequacy of the linear model relative to the quadratic one was 
tested by likelihood ratio test. Multicollinearity of the dependent variables was assessed by 
computing the variance inflation factor; values ranged from 1.02 to 1.21, suggesting lack of 
collinearity. 
All multivariate models were adjusted for age (continuous), smoking status 
(current/other), LTPA (3 categories), OPA (physical/non-physical) and BMI (except for 
anthropometry). Further adjustments were performed on: weight (continuous) for WC; 
hypertensive drug treatment (yes/no) for BP; lipid lowering drug treatment (yes/no) for lipid 
markers and antidiabetic drug treatment (yes/no) for glucometabolic markers. Sensitivity 
analyses were performed by further stratifying on tertiles of age. Statistical significance was 
assessed for a two-sided test with p<0.05. 
Ethical statement 
The CoLaus study was approved by the Ethics Committee of the University of 
Lausanne and all participants gave their signed informed consent before entering the study. 
RESULTS 
Characteristics of excluded participants 
Of the initial 3704 participants invited to the sub-study on frailty, 3550 (95.8%) 
accepted. A further 82 (2.3%) participants were excluded because of issues related to grip 
strength measurement. Included and excluded participants’ characteristics are presented in 
Supplementary Table 1. Included participants were more likely right-handed than the 
excluded ones, while no significant differences were found for all other variables analyzed.   
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The final sample consisted of 3468 participants; their characteristics overall and 
according to gender are summarized in Supplementary Table 2. Men had higher grip 
strength, were more likely to be current or former smoker, to have a university level of 
education, to be full-time worker, to perform a physical job, and to have a higher 10-year CV 
absolute risk than women. 
Association of grip strength with cardiovascular risk markers 
The bivariate and multivariate-adjusted associations using linear regression between 
grip strength and CV risk markers are described in Table 1; the corresponding changes in CV 
risk markers due to a 5 kg-increase in grip strength are described in Table 2. Bivariate 
analysis showed that grip strength was negatively associated with fat mass, systolic BP, 
fasting glucose, leptin, hs-CRP and homocysteine in both genders. In men, grip strength was 
positively associated with diastolic BP, total and LDL-cholesterol, and negatively associated 
with IL-6; in women, grip strength was negatively associated with triglycerides and uric acid. 
Finally, grip strength was negatively associated with 10-year CV absolute risk as assessed by 
the SCORE equation in both genders (Pearson correlation coefficient: women: -0.245, 
p<0.001, men: -0.264, p<0.001). Most of the previous associations were no longer 
significant after multivariate adjustment. In both genders, grip strength was negatively 
associated with WC, fat mass and hs-CRP; in men, grip strength was positively associated 
with BMI and negatively associated with leptin (Table 1 and 2). 
Comparison between linear and quadratic models for homocysteine, total and LDL-
cholesterol are expressed in Supplementary Table 3. For log-transformed homocysteine, 
total and LDL-cholesterol, the quadratic regression model showed a better fit than the linear 
one. An inverse U-shaped association between grip strength and total and LDL-cholesterol 
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was found in women. A U-shaped association between grip strength and homocysteine was 
found in men.  
The linear associations between grip strength and CV risk markers stratified by 
tertiles of age are represented in Supplementary Tables 4 (women) and 5 (men), and the 
quadratic associations for homocysteine, total and LDL-cholesterol in Supplementary Table 
6. Most associations remained identical through tertiles of age.   
DISCUSSION 
This study assessed the associations between grip strength and a large panel of CV 
risk markers in a population-based setting. Our results suggest that grip strength is only 
moderately associated with CV risk markers and CV absolute risk. Thus, the reported 
associations between grip strength and CV disease might not be mediated via those CV risk 
markers. 
Grip strength, anthropometric and adiposity-related markers 
Grip strength was negatively associated with WC and fat mass in both genders, and 
positively with BMI in men. The negative association with WC is consistent with a large 
cross-sectional population-based study 8 but not with another including older participants 
10. Fitness and regular exercise have been shown to improve body composition by reducing 
fat mass 19, 20, but the effect of grip strength on CV mortality has also been suggested to be 
independent of body composition 21. According to a large 8.3-year follow-up study 22, 
muscle strength (measured using bench and leg press tests) showed a strong inverse 
prediction of excessive WC and fat mass after adjusting for fitness. The results suggest that 
grip strength is negatively related to body fat and positively to BMI, possibly due to the 
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larger muscle mass of overweight and obese subjects. Still, the changes in WC, fat mass and 
BMI induced by 5 kg change in grip strength were modest (1.2 cm, 1.2% and 0.30 kg/m2, 
respectively) at the individual level. 
A negative association between grip strength and leptin was found in men but not in 
women, and no association was observed for adiponectin. These findings are partly in 
agreement with a cross-sectional study 10 where no association was found between grip 
strength and adiposity-related hormones. Exercise has been shown to decrease leptin levels 
23 but not adiponectin levels 23. Overall, our results suggest that grip strength is moderately 
associated with leptin levels in men, but further studies should be conducted to confirm this 
association. 
Grip strength, blood pressure, lipids and glucometabolic markers 
On multivariate analysis, no significant association was found between grip strength 
and BP levels. These findings are in agreement with a recent cross-sectional study 10 but not 
with another 8. Fitness and regular exercise have been shown to decrease BP levels 24, while 
muscle strength (measured using bench and leg press tests) showed no effect on 19-year 
incidence of hypertension after adjustment for fitness 25. Overall, our results suggest that 
grip strength is not associated with BP levels, or that the association is too small to be 
detected using our sample size. 
In both genders, an inverse U-shaped association between grip strength and total 
and LDL-cholesterol was found, this association being more prominent in women. 
Conversely, no association was found between grip strength and HDL-cholesterol, 
triglycerides and apolipoprotein B. These findings are partly in agreement with a cross-
sectional study 10 which found no association between grip strength and triglycerides, total 
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and HDL-cholesterol. The inverse U-shaped association between grip strength and total and 
LDL cholesterol might be explained by two differing phenomena: first, increased fitness is 
associated with an improved lipids profile 19, which would explain the negative association 
between high grip strength values and lipid levels on the right hand side of the curve. 
Second, low lipid levels have been associated with mortality in an elderly cohort 26; as low 
grip strength is also associated with increased mortality, this would explain the positive 
association between grip strength and lipid levels on the left hand side of the curve. Thus, 
our results suggest that grip strength has a complex association with the lipid profile, high 
values of grip strength being associated with a “beneficial” low lipid profile, while low values 
of grip strength are associated with a “deleterious” low lipid profile. Nevertheless, these 
findings should be further confirmed in other studies. 
No association was found between grip strength and fasting glucose and insulin, a 
finding in agreement with two cross-sectional studies 8, 10. Fitness and regular exercise have 
been shown to improve glucose profile 19, 27 while muscle strength showed no beneficial 
effects on glucose levels after adjustment for fitness 28. The results suggest that grip 
strength is not associated with glucose metabolism or that the association is too small to be 
detected using the current sample size. 
Grip strength and inflammation 
Grip strength was negatively associated with hs-CRP levels, a finding in agreement 
with the literature 9, 10. Fitness and regular exercise decrease CRP levels 29, probably by a 
decrease in adiposity levels and adiposity-related inflammation. Indeed, a previous study 30 
showed an association between poor muscle quantity and quality (i.e. fat deposition in 
skeletal muscle) and adiposity-related inflammation. Conversely, the association between 
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grip strength and IL-6 or TNF-α is still a matter of debate : some studies reported a negative 
association 9, 31 while others reported no association 10. Thus, our findings confirm that grip 
strength is negatively associated with hs-CRP levels, but not with IL-6 or TNF-α. Still, the 
change in CRP levels were moderate (8.5% decrease per 5 kg increase in grip strength) 
compared for example to the reduction induced by statin treatment 32. Thus, whether 
decrease in CRP levels due to grip strength is clinically significant remains to be assessed. 
Grip strength, homocysteine and uric acid 
A U-shaped association between grip strength and homocysteine was found in men. 
Low grip strength was associated with high homocysteine levels, a finding also reported in a 
recent review 33, while the high homocysteine levels found among subjects with high grip 
strength deserve further clarification. Finally, no clear association was found between grip 
strength and uric acid levels, a finding in agreement with the literature 34. 
Grip strength and cardiovascular absolute risk 
Grip strength was negatively associated with CV absolute risk in both genders, a 
finding in agreement with the beneficial effects of fitness 11 and muscle strength 7 on CV 
mortality.   
Study strengths and limitations 
This is one of the largest studies assessing the associations between grip strength 
and a wide panel of cardiovascular risk markers. Importantly, the specific effects of grip 
strength were separated from those of LTPA and OPA.  
This study also has several limitations worth acknowledging. Firstly, grip strength was 
assessed on the right hand whereas approximately 8% of our participants were left-handed. 
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However, it has been shown that grip strength does not differ between dominant and non-
dominant hands in left-handed people 5. Secondly, the cross-sectional design of our study 
precludes the assessment of any causal effect of grip strength on CV risk markers; the 
ongoing follow-up of the CoLaus participants will enable assessing the prospective effects of 
grip strength on CV risk markers. Thirdly, only participants aged between 50 and 75 were 
included, so our findings cannot be extrapolated to younger or older ages. Finally, most of 
the associations between grip strength and CV risk markers were weak, suggesting that grip 
strength might exert its effect on CV disease via other pathways, such as changes in 
endothelial function or autonomic nervous system. 
Conclusion 
In a population-based sample aged between 50 and 75 years, grip strength was only 
moderately associated with some CV risk markers. Thus, the reported associations between 
grip strength and CV disease might not be mediated via CV risk markers. 
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TABLES 
Table 1: bi- and multivariate associations between grip strength and cardiovascular risk markers. 
 
 Pearson correlation 
coefficient 
Multivariate-adjusted 
standardized coefficient 
 Women Men Women Men 
Anthropometry     
Body mass index (kg/m2) -0.034  0.022 -0.000   0.092 ** 
Waist circumference (cm) -0.005  0.039  -0.069 1 **  -0.114 1 ** 
Fat mass (%) -0.170** -0.198** -0.078 * -0.084 * 
Blood pressure (mmHg)     
Systolic -0.096** -0.074*  0.038 2  0.003 2 
Diastolic  0.007  0.068*  0.015 2  0.045 2 
Lipid markers (mmol/L)     
Total cholesterol  -0.028  0.106**  0.004 3   0.082 3 *  
HDL-cholesterol  0.015  0.002 -0.001 3  0.029 3 
LDL-cholesterol  -0.025  0.082* 0.001 3   0.055 3 *  
Triglycerides § -0.064*  0.048 -0.003 3  0.026 3 
Apolipoprotein B (mg/dL) -0.007  0.010  0.003 3 -0.006 3 
Glucometabolic markers     
Fasting glucose (mmol/L) -0.048* -0.071* -0.006 4 -0.036 4 
Insulin (µU/mL) § -0.031 -0.049  0.007 4 -0.032 4 
Adipokines (µU/mL)     
Leptin § -0.074* -0.065* -0.026 5 -0.059 5 * 
Adiponectin § -0.036 -0.014 -0.024 5  0.012 5 
Inflammatory markers     
hs-CRP (mg/L) § -0.101** -0.079* -0.071 5 * -0.052 5 * 
IL-6 (pg/mL) § -0.009 -0.071* -0.009 5 -0.054 5 
TNF-α (pg/mL) § -0.005 -0.043  0.016 5 -0.024 5 
Homocysteine (µmol/L) § -0.109** -0.060* -0.022 5   0.032 5 
Uric acid (µmol/L) -0.059*  0.012  0.017 5  0.018 5 
 
§, log-transformed. hs-CRP, high sensitivity C-reactive protein; IL-6, interleukin 6; TNF-α, tumour 
necrosis factor alpha. Bivariate associations assessed using Pearson correlation or multivariable 
linear regression; results are expressed as Pearson correlation coefficient or as multivariate-adjusted 
standardized coefficient. Multivariable linear model was adjusted for age, current smoking, leisure-
time physical activity and occupational physical activity, with a further adjustment on 1 weight; 2 
body mass index and antihypertensive drug treatment; 3 body mass index and lipid lowering drug 
treatment; 4 body mass index and antidiabetic drug treatment; 5 body mass index. *, p<0.05; **, 
p<0.001. 
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Table 2: Unadjusted and multivariate-adjusted changes in cardiovascular risk marker levels per 5 kg increase in grip strength, stratified by gender. 
 Women Men 
 Unadjusted P-value Multivariate-adjusted P-value Unadjusted P-value Multivariate-adjusted P-value 
Anthropometry         
Body mass index (kg/m2) -0.16 (-0.37 ; 0.05) 0.143 0.00 (-0.22 ; 0.22) 0.985 0.05 (-0.07 ; 0.17) 0.384 0.22 (0.10 ; 0.35) <0.001 
Waist circumference (cm)  -0.06 (-0.60 ; 0.49) 0.839 -0.82 (-1.13 ; -0.52) 1 <0.001 0.26 (-0.07 ; 0.59) 0.121 -0.77 (-0.93 ; -0.61)  1 <0.001 
Fat mass (%) -1.23 (-1.55 ; -0.90) <0.001 -0.56 (-0.89 ; -0.22) 0.001 -0.63 (-0.78 ; -0.47) <0.001 -0.27 (-0.43 ; -0.11) 0.001 
Blood pressure (mmHg)         
Systolic  -1.67 (-2.46 ; -0.89) <0.001 0.66 (-0.12 ; 1.43) 2 0.098 -0.77 (-1.28 ; -0.26) 0.003 0.04 (-0.48 ; 0.56) 2 0.892 
Diastolic  0.07 (-0.38 ; 0.52) 0.762 0.15 (-0.31 ; 0.61) 2 0.522 0.44 (0.12 ; 0.76) 0.007 0.29 (-0.05 ; 0.63) 2 0.090 
Lipid markers (mmol/L)         
Total cholesterol  -0.03 (-0.07 ; 0.02) 0.230 0.00 (-0.04 ; 0.05) 3 0.863 0.06 (0.03 ; 0.09) <0.001 0.05 (0.02 ; 0.08) 3 0.002 
HDL-cholesterol 0.01 (-0.01 ; 0.03) 0.505 0.00 (-0.02 ; 0.02) 3 0.969 0.00 (-0.01 ; 0.01) 0.939 0.01 (0.00 ; 0.02) 3 0.257 
LDL-cholesterol  -0.02 (-0.06 ; 0.02) 0.273 0.00 (-0.04 ; 0.04) 3 0.961 0.04 (0.02 ; 0.07) 0.001 0.03 (0.00 ; 0.06) 3 0.036 
Triglycerides § -2.7 (-4.5 ; -0.8) 0.006 -0.1 (-2.0 ; 1.7) 3 0.884 1.6 (-0.1 ; 3.2) 0.058 0.8 (-0.8 ; 2.5) 3 0.312 
Apolipoprotein B (mg/dL) -0.91 (-7.02 ; 5.20) 0.770 0.35 (-6.21 ; 6.90) 3 0.918 0.83 (-3.34 ; 5.01) 0.695 -0.52 (-5.01 ; 3.97) 3 0.820 
Glucometabolic markers         
Fasting glucose (mmol/L) -0.05 (-0.10 ; 0.00) 0.036 -0.01 (-0.05 ; 0.04) 4 0.777 -0.06 (-0.10 ; -0.02) 0.005 -0.03 (-0.07 ; 0.01) 4 0.116 
Insulin (µU/mL) § -1.6 (-4.0 ; 0.9) 0.215 0.4 (-2.0 ; 2.7) 4 0.764 -1.7 (-3.4 ; 0.1) 0.069 -1.1 (-2.7 ; 0.6) 4 0.201 
Adipokines (µU/mL)         
Leptin § -4.9 (-8.0 ; -1.7) 0.003 -1.8 (-4.4 ; 0.9) 5 0.198 -2.9 (-5.2 ; -0.5) 0.016 -2.7 (-4.6 ; -0.6) 5 0.010 
Adiponectin § -2.1 (-4.8 ; 0.6) 0.129 -1.4 (-4.2 ; 1.5) 5 0.337 -0.5 (-2.4 ; 1.4) 0.598 0.4 (-1.6 ; 2.5) 5 0.671 
Inflammatory markers         
hs-CRP (mg/L) § -9.6 (-13.5 ; -5.5) <0.001 -6.8 (-10.7 ; -2.8) 5 0.001 -4.7 (-7.6 ; -1.8) 0.002 -3.2 (-6.1 ; -0.2) 5 0.039 
IL-6 (pg/mL) § -1.1 (-6.6 ; 4.8) 0.713 -1.1 (-7.0 ; 5.2) 5 0.730 -5.4 (-9.1 ; -1.5) 0.007 -4.1 (-8.2 ; 0.1) 5 0.055 
TNF-α (pg/mL) § -0.4 (-4.0 ; 3.3) 0.828 1.2 (-2.6 ; 5.3) 5 0.534 -2.1 (-4.5 ; 0.4) 0.094 -1.2 (-3.8 ; 1.5) 5 0.392 
Homocysteine (µmol/L) § -2.9 (-4.0 ; -1.7) <0.001 -0.6 (-1.8 ; 0.7) 5 0.359 -1.1 (-2.0 ; -0.2) 0.019 0.6 (-0.4 ; 1.6) 5 0.212 
Uric acid (µmol/L) -3.93 (-6.92 ; -0.94) 0.010 1.12 (-1.79 ; 4.04) 5 0.449 0.53 (-1.75 ; 2.80) 0.650 0.84 (-1.52 ; 3.21) 5 0.485 
hs-CRP, high sensitivity C-reactive protein; IL-6, interleukin 6; TNF-α, tumour necrosis factor alpha. Statistical analyses performed using linear regression. 
Results are expressed as effect of a 5 kg increase in grip strength and (95% confidence interval). §, on log-transformed data; results are expressed as % 
change of the risk marker related to a 5 kg increase in grip strength. Multivariate adjustment for age, current smoking, leisure-time physical activity and 
occupational physical activity, with a further adjustment on 1 weight; 2 body mass index and antihypertensive drug treatment; 3 body mass index and lipid 
lowering drug treatment; 4 body mass index and antidiabetic drug treatment; 5 body mass index. 
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SUPPLEMENTARY INFORMATION 
Supplementary table 1: socio-demographic and clinical characteristics of excluded and included 
participants. 
 Included Excluded P-value 
N 3468 82  
Right-handedness (%) 91.6 79.0 <0.001 
Grip strength (kg) 33.5 ± 10.8 28.2 ± 12.9 <0.001 
Age (years) 60.8 ± 6.8 61.3 ± 7.5 0.46 
Smoking    0.86 
 Former (%) 36.6 34.6  
Never (%)  40.2 43.2  
Current (%) 23.2 22.2  
University level (%) 16.3 12.4 0.34 
Working    0.88 
Full time (%) 46.9 48.2  
Part time (%) 46.8 46.9  
None (%) 6.3 4.9  
Physical job (%) 15.7 21.3 0.18 
10-year CV absolute risk (%) 3.3 ± 3.9 3.6 ± 4.5 0.51 
Body mass index (kg/m2) 26.4 ± 4.7 26.4 ± 4.8 0.93 
Fat mass (%) 32.1 ± 8.7 33.2 ± 7.0 0.24 
Hypertension (%) 50.1 53.7 0.53 
Dyslipidemia (%) 41.1 45.1 0.47 
Diabetes (%)  9.8 13.4 0.27 
 
CV, cardiovascular. Results are expressed as mean ± standard deviation or as percentage. Statistical 
analyses by chi-square for categorical variables or Student’s t-test for quantitative variables. 
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Supplementary table 2: Characteristics of participants, overall and by gender 
 All Women Men P-value 
N 3468 1891 1577  
Right-handedness (%) 91.6 92.1 91.1 0.49 
Grip strength (kg) 33.5 ± 10.8 26.0 ± 5.4 42.6 ± 8.4 <0.001 
Age (years) 60.8 ± 6.8 60.8 ± 6.8 60.7 ± 6.8 0.80 
Smoking    <0.001 
Former (%) 36.6 29.2 45.5  
Never (%) 40.2 49.4 29.1  
Current (%) 23.2 21.4 25.4  
University level (%) 16.3 11.8 21.7 <0.001 
Working    <0.001 
Full time (%) 46.9 39.4 55.8  
Part time (%) 46.8 54.4 37.7  
None (%) 6.3 6.2 6.5  
Physical job (%) 15.7 13.0 18.9 <0.001 
10-year CV absolute risk (%) 3.3 ± 3.9 2.3 ± 3.1 4.6  ± 4.5 <0.001 
Anthropometry     
Body mass index (kg/m2) 26.4 ± 4.7 25.8 ± 5.0 27.1 ± 4.1 <0.001 
Waist circumference (cm) 91.5 ± 13.6 85.9 ± 12.8 98.2 ± 11.3 <0.001 
Fat mass (%) 32.1 ± 8.7 37.0 ± 7.7 26.1 ± 5.4 <0.001 
Lean mass (%) 67.9 ± 8.7 63.0 ± 7.7 73.9 ± 5.4 <0.001 
Blood pressure     
Systolic BP (mmHg) 133.7 ± 18.5 130.8 ± 18.7 137.1 ± 17.6  <0.001 
Diastolic BP (mmHg) 80.7 ± 10.9 79.1 ± 10.6 82.8 ± 11.0 <0.001 
Hypertension (%) 50.1 43.3 58.3 <0.001 
Lipid markers     
Total cholesterol (mmol/L) 5.8 ± 1.0 5.9 ± 1.0 5.6 ± 1.0 <0.001 
HDL-cholesterol (mmol/L) 1.7 ± 0.5 1.8 ± 0.5 1.5 ± 0.4 <0.001 
LDL-cholesterol (mmol/L) 3.5 ± 0.9 3.5 ± 0.9 3.4 ± 0.9 <0.001 
Triglycerides  § 1.4 ± 1.0 1.3 ± 0.7 1.7 ± 1.3 <0.001  
Apolipoprotein B (mg/dL) 182.1 ± 140.0 182.4 ± 141.7 181.7 ± 137.9 0.90 
Dyslipidemia (%) 88.9 89.3 88.3 0.36 
Glucometabolic markers     
Fasting glucose (mmol/L) 5.7 ± 1.3 5.5 ± 1.1 6.0 ± 1.4 <0.001 
Insulin (µU/mL) § 9.2 ± 6.4 8.3 ± 5.4 10.2 ± 7.3 <0.001  
Diabetes (%)  9.8 5.7 14.6 <0.001 
Adipokines     
Leptin (µU/mL) § 14.2 ± 11.1 18.0 ± 12.0 9.5 ± 7.7 <0.001  
Adiponectin (µU/mL) § 10767 ± 8610 13213 ± 9754 7860 ± 5801 <0.001  
Inflammatory markers     
hs-CRP (mg/L) § 2.7 ± 3.6 2.8 ± 3.8 2.6 ± 3.4 0.20  
IL-6 (pg/mL) § 9.0 ± 105.4 9.1 ± 128.1 8.8 ± 69.2 <0.001  
TNF-α (pg/mL) § 5.3 ± 18.0 5.6 ± 23.2 4.9 ± 8.2 0.25  
Homocysteine (µmol/L) § 11.0 ± 4.7 10.0 ± 3.3 12.2 ± 5.7 <0.001 
Uric acid (µmol/L) 324.3 ± 85.0 286.3 ± 71.0 369.8 ± 77.6 <0.001 
 
CV, cardiovascular. §, on log-transformed data. Results are expressed as mean ± standard deviation or as 
percentage. Statistical analyses by chi-square or Student’s t-test. 
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Supplementary table 3: comparison between the linear and the quadratic model for the associations between grip strength and 
selected cardiovascular risk markers. 
 Grip strength Grip strength2 Likelihood ratio §§ P-value 
Men     
Total cholesterol, linear model 0.082 1 - 3.88 0.049 
Total cholesterol, quadratic model 0.367 1 * -0.288 1   
LDL cholesterol, linear model 0.055 1 - 3.54 0.060 
LDL cholesterol, quadratic model 0.345 1 * -0.293 1   
Homocysteine §, linear model 0.032 - 7.11 0.008 
Homocysteine §, quadratic model -0.488 * 0.526 *   
Women     
Total cholesterol, linear model 0.004  1 - 9.23 0.002 
Total cholesterol, quadratic model 0.432 1 * -0.434 1 *   
LDL cholesterol, linear model 0.001 1 - 8.22 0.004 
LDL cholesterol, quadratic model 0.427 1 * -0.432 1 *   
Homocysteine §, linear model -0.022 - 1.23 0.268 
Homocysteine §, quadratic model -0.271 0.252   
§ log-transformed, §§ likelihood ratio test comparing the quadratic to the linear model. Results are expressed as standardized 
coefficients. Adjustments for age, current smoking, leisure-time physical activity, occupational physical activity and body mass index 
with a further adjustment on 1 lipid lowering drug treatment; *, p<0.05; **, p<0.001. 
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Supplementary table 4: multivariate-adjusted changes in cardiovascular risk marker levels per 5 kg increase in grip strength, women, stratified 
by tertile of age 
 All P-value First tertile P-value Second tertile P-value Third tertile P-value 
Anthropometry         
Body mass index (kg/m2) 0.00 (-0.22 ; 0.22) 0.985 -0.28 (-0.67 ; 0.10) 0.151 -0.01 (-0.39 ; 0.37) 0.946 0.33 (-0.04 ; 0.71) 0.079 
Waist circumference (cm)  -0.82 (-1.13 ; -0.52) 1 <0.001 -1.00 (-1.49 ; -0.51) 1 <0.001 -0.68 (-1.17 ; -0.18) 1 0.008 -1.18 (-1.77 ; -0.59) 1 <0.001 
Fat mass (%) -0.56 (-0.89 ; -0.22) 0.001 -1.21 (-1.78 ; -0.64) <0.001 -0.27 (-0.86 ; 0.32) 0.362 -0.43 (-0.99 ; 0.13) 0.132 
Blood pressure (mmHg)         
Systolic  0.66 (-0.12 ; 1.43) 2 0.098 -0.60 (-1.71 ; 0.50) 2 0.284 1.73 (0.33 ; 3.12) 2 0.015 0.02 (-1.51 ; 1.56) 2 0.979 
Diastolic  0.15 (-0.31 ; 0.61) 2 0.522 -0.51 (-1.25 ; 0.22) 2 0.170 0.91 (0.12 ; 1.71) 2 0.025 0.52 (-0.32 ; 1.37) 2 0.222 
Lipid markers         
Total cholesterol (mmol/L)  0.00 (-0.04 ; 0.05) 3 0.863 -0.08 (-0.15 ; -0.01) 3 0.035 0.07 (-0.01 ; 0.15) 3 0.067 -0.01 (-0.08 ; 0.07) 3 0.893 
HDL-cholesterol (mmol/L) 0.00 (-0.02 ; 0.02) 3 0.969 -0.02 (-0.05 ; 0.01) 3 0.277 0.00 (-0.03 ; 0.04) 3 0.752 0.01 (-0.02 ; 0.05) 3 0.475 
LDL-cholesterol  (mmol/L) 0.00 (-0.04 ; 0.04) 3 0.961 -0.06 (-0.13 ; 0.01) 3 0.071 0.05 (-0.02 ; 0.12) 3 0.147 -0.01 (-0.08 ; 0.07) 3 0.877 
Triglycerides  (mmol/L) § -0.1 (-2.0 ; 1.7) 3 0.884 -0.6 (-3.6 ; 2.6) 3 0.719 1.7 (-1.5 ; 5.0) 3 0.306 -2.4 (-5.6 ; 0.9) 3 0.154 
Apolipoprotein B (mg/dL) 0.35 (-6.21 ; 6.90) 3 0.918 -4.67 (-15.60 ; 6.27) 3 0.402 4.23 (-7.94 ; 16.40) 3 0.495 0.49 (-10.10 ; 11.08) 3 0.927 
Glucometabolic markers         
Fasting glucose (mmol/L) -0.01 (-0.05 ; 0.04) 4 0.777 -0.01 (-0.07 ; 0.06) 4 0.860 0.02 (-0.06 ; 0.11) 4 0.615 -0.04 (-0.11 ; 0.03) 4 0.288 
Insulin (µU/mL) § 0.4 (-2.0 ; 2.7) 4 0.764 0.7 (-3.1 ; 4.6) 4 0.725 0.5 (-3.6 ; 4.7) 4 0.828 -0.9 (-4.9 ; 3.3) 4 0.664 
Adipokines (µU/mL)         
Leptin § -1.8 (-4.4 ; 0.9) 5 0.198 -3.9 (-7.9 ; 0.4) 5 0.072 -2.4 (-7.0 ; 2.4) 5 0.314 1.2 (-3.7 ; 6.4) 5 0.639 
Adiponectin § -1.4 (-4.2 ; 1.5) 5 0.337 0.1 (-4.4 ; 4.9) 5 0.963 -3.6 (-8.4 ; 1.5) 5 0.161 -0.5 (-5.3 ; 4.5) 5 0.838 
Inflammatory markers         
hs-CRP (mg/L) § -6.8 (-10.7 ; -2.8) 5 0.001 -7.7 (-13.9 ; -1.0) 5 0.024 -3.8 (-10.3 ; 3.3) 5 0.289 -8.5 (-15.3 ; -1.2) 5 0.024 
IL-6 (pg/mL) § -1.1 (-7.0 ; 5.2) 5 0.730 3.4 (-7.3 ; 15.3) 5 0.552 -5.8 (-15.3 ; 4.7) 5 0.265 -0.6 (-10.7 ; 10.6) 5 0.909 
TNF-α (pg/mL) § 1.2 (-2.6 ; 5.3) 5 0.534 3.8 (-3.1 ; 11.1) 5 0.288 1.9 (-4.5 ; 8.7) 5 0.574 -4.1 (-10.4 ; 2.6) 5 0.223 
Homocysteine (µmol/L) § -0.6 (-1.8 ; 0.7) 5 0.359 0.4 (-1.6; 2.5) 5 0.682 0.3 (-1.7; 2.3) 5 0.790 -4.4 (-6.6; -2.1) 5 <0.001 
Uric acid (µmol/L) 1.12 (-1.79 ; 4.04) 5 0.449 -1.28 (-5.87 ; 3.32) 5 0.586 4.68 (-0.19 ; 9.56) 5 0.060 -2.6 (-8.13; 2.99) 5 0.365 
hs-CRP, high sensitivity C-reactive protein; IL-6, interleukin 6; TNF-α, tumour necrosis factor alpha. Statistical analyses performed using linear 
regression. Results are expressed as effect of a 5 kg increase in grip strength and (95% confidence interval). §, on log-transformed data; results 
are expressed as % change of the risk marker related to a 5 kg increase in grip strength. Multivariate adjustment for age (not for tertiles of age) 
current smoking, leisure-time physical activity and occupational physical activity, with a further adjustment on 1 weight; 2 body mass index and 
antihypertensive drug treatment; 3 body mass index and lipid lowering drug treatment; 4 body mass index and antidiabetic drug treatment; 5 
body mass index. 
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Supplementary table 5: multivariate-adjusted changes in cardiovascular risk marker levels per 5 kg increase in grip strength, men, stratified by 
tertile of age 
 All P-value First tertile P-value Second tertile P-value Third tertile P-value 
Anthropometry         
Body mass index (kg/m2) 0.22 (0.10 ; 0.35) <0.001 0.22 (0.01 ; 0.43) 0.038 0.30 (0.10 ; 0.51) 0.004 0.12 (-0.12 ; 0.35) 0.328 
Waist circumference (cm)  -0.77 (-0.93 ; -0.61)  1 <0.001 -0.71 (-0.96 ; -0.46) 1 <0.001 -0.78 (-1.06 ; -0.50) 1 <0.001 -0.94 (-1.24 ;-0.63) 1 <0.001 
Fat mass (%) -0.27 (-0.43 ; -0.11) 0.001 -0.17 (-0.45 ; 0.10) 0.215 -0.26 (-0.53 ; 0.02) 0.065 -0.54 (-0.81 ; -0.27) <0.001 
Blood pressure (mmHg)         
Systolic  0.04 (-0.48 ; 0.56) 2 0.892 0.34 (-0.43 ; 1.11) 2 0.386 0.21 (-0.67 ; 1.09) 2 0.642 -1.01 (-2.05 ; 0.03) 2 0.056 
Diastolic  0.29 (-0.05 ; 0.63) 2 0.090 0.21 (-0.35 ; 0.77) 2 0.458 0.74 (0.19 ; 1.30) 2 0.008 0.03 (-0.61 ; 0.66) 2 0.935 
Lipid markers         
Total cholesterol (mmol/L)  0.05 (0.02 ; 0.08) 3 0.002 0.06 (0.00 ; 0.11) 3 0.033 0.00 (-0.05 ; 0.05) 3 0.946 0.11 (0.05 ; 0.17) 3 <0.001 
HDL-cholesterol (mmol/L) 0.01 (0.00 ; 0.02) 3 0.257 0.00 (-0.01 ; 0.02) 3 0.630 0.01 (-0.01 ; 0.02) 3 0.531 0.01 (-0.01 ; 0.03) 3 0.527 
LDL-cholesterol  (mmol/L) 0.03 (0.00 ; 0.06) 3 0.036 0.04 (-0.01 ; 0.08) 3 0.091 -0.03 (-0.08 ; 0.02) 3 0.237 0.09 (0.04 ; 0.14) 3 <0.001 
Triglycerides  (mmol/L) § 0.8 (-0.8 ; 2.5) 3 0.312 0.5 (-2.3 ; 3.5) 3 0.712 1.4 (-1.3 ; 4.2) 3 0.311 0.6 (-2.1 ; 3.4) 3 0.656 
Apolipoprotein B (mg/dL) -0.52 (-5.01 ; 3.97) 3 0.820 -4.33 (-12.63 ; 3.96) 3 0.305 -2.09 (-8.60 ; 4.37) 3 0.525 4.67 (-3.72 ; 13.06) 3 0.275 
Glucometabolic markers         
Fasting glucose (mmol/L) -0.03 (-0.07 ; 0.01) 4 0.116 0.00 (-0.06 ; 0.05) 4 0.944 -0.07 (-0.14 ; -0.01) 4 0.029 -0.02 (-0.10 ; 0.06) 4 0.621 
Insulin (µU/mL) § -1.1 (-2.7 ; 0.6) 4 0.201 -3.2 (-6.0 ; -0.3) 4 0.029 -0.1 (-2.9 ; 2.7) 4 0.934 -0.3 (-3.2 ; 2.6) 4 0.814 
Adipokines (µU/mL)         
Leptin § -2.7 (-4.6 ; -0.6) 5 0.010 -3.9 (-7.3 ; -0.4) 5 0.031 -0.3 (-3.5 ; 3.0) 5 0.859 -4.9 (-8.4 ; -1.4) 5 0.007 
Adiponectin § 0.4 (-1.6 ; 2.5) 5 0.671 -0.2 (-3.5 ; 3.2) 5 0.904 -1.3 (-4.6 ; 2.1) 5 0.437 2.1 (-1.5 ; 5.9) 5 0.252 
Inflammatory markers         
hs-CRP (mg/L) § -3.2 (-6.1 ; -0.2) 5 0.039 -1.1 (-5.9 ; 3.9) 5 0.657 -2.1 (-7.0 ; 3.10) 5 0.416 -8.1 (-13.3 ; -2.6) 5 0.004 
IL-6 (pg/mL) § -4.1 (-8.2 ; 0.1) 5 0.055 -2.3 (-9.2 ; 5.1) 5 0.534 -1.9 (-9.0 ; 5.7) 5 0.611 -9.0 (-15.5 ; -1.9) 5 0.013 
TNF-α (pg/mL) § -1.2 (-3.8 ; 1.5) 5 0.392 -2.2 (-6.2 ; 2.1) 5 0.308 -0.5 (-4.9 ; 4.0) 5 0.811 -0.4 (-5.5 ; 4.9) 5 0.869 
Homocysteine (µmol/L) § 0.6 (-0.4 ; 1.6) 5 0.212 2.1 (0.5 ; 3.7) 5 0.009 0.3 (-1.4 ; 2.0) 5 0.741 -1.9 (-3.7 ; 0.0) 5 0.050 
Uric acid (µmol/L) 0.84 (-1.52 ; 3.21) 5 0.485 1.80 (-1.92 ; 5.52) 5 0.342 0.34 (-3.84 ; 4.52) 5 0.873 -0.40 (-4.78 ; 3.98) 5 0.858 
hs-CRP, high sensitivity C-reactive protein; IL-6, interleukin 6; TNF-α, tumour necrosis factor alpha. Statistical analyses performed using linear 
regression. Results are expressed as effect of a 5 kg increase in grip strength and (95% confidence interval). §, on log-transformed data; results 
are expressed as % change of the risk marker related to a 5 kg increase in grip strength. Multivariate adjustment for age (not for tertiles of age), 
current smoking, leisure-time physical activity and occupational physical activity, with a further adjustment on 1 weight; 2 body mass index and 
antihypertensive drug treatment; 3 body mass index and lipid lowering drug treatment; 4 body mass index and antidiabetic drug treatment; 5 
body mass index. 
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Supplementary table 6: multivariate associations between grip strength and selected cardiovascular risk markers using quadratic 
model, stratified by tertile of age 
 
 All First tertile Second tertile Third tertile 
 Grip strength Grip strength2 Grip strength Grip strength2 Grip strength Grip strength2 Grip strength Grip strength2 
Men         
Total cholesterol 0.367 1 * -0.288 1 0.090 1 0.010 1 0.483 1 -0.497 1 0.456 1 -0.315 1 
LDL cholesterol 0.345 1 * -0.293 1 0.046 1 0.034 1 0.551 1 -0.622 1 * 0.304 1 -0.160 1 
Homocysteine § -0.488 * 0.526 * -0.228 0.350 -0.305 0.341 -0.745 * 0.712 * 
Women         
Total cholesterol 0.432 1 * -0.434 1 * 0.694 1 * -0.773 1 * 0.023 1 0.059 1 0.302 1 -0.314 1 
LDL cholesterol 0.427 1 * -0.432 1 * 0.662 1 * -0.729 1 * 0.065 1 -0.004 1 0.294 1 -0.304 1 
Homocysteine § -0.271 0.252 0.050 -0.016 -0.033 0.056 -0.619 * 0.501 
 
§ log-transformed. Statistical analyses performed using quadratic regression model. Results are expressed as standardized coefficients. 
Adjustments for age, current smoking, leisure-time physical activity, occupational physical activity and body mass index with a further 
adjustment on 1 lipid lowering drug treatment; *, p<0.05; **, p<0.001. 
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